Correction: Kynurenine pathway is altered in patients with SLE and associated with severe fatigue (Lupus Science and Medicine (2018) 5 (e000254) DOI: 10.1136/lupus-2017-000254);Kynurenine pathway is altered in patients with SLE and associated with severe fatigue

Lupus Science and Medicine

Volumn 5, Issue 1, 2018, Pages

  Åkesson, Karolina ^a   Pettersson, Susanne ^a,b   Ståhl, Sara ^c   Surowiec, Izabella ^d   Hedenström, Mattias ^d   Eketjäll, Susanna ^b   Trygg, Johan ^d   Jakobsson, Per Johan ^a   Gunnarsson, Iva ^a   Svenungsson, Elisabet ^a   Idborg, Helena ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

autoimmune diseases; autoimmunity; disease activity; systemic lupus erythematosus

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; QUINOLINIC ACID; TRYPTOPHAN;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; METABOLITE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 85048132511     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2017-000254corr1     Document Type: Erratum

References (48)

1. Meszaros ZS, Perl A, Faraone SV. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry 2012;73:993.
2. Pettersson S, Lovgren M, Eriksson LE, et al. An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life. Scand J Rheumatol 2012;41:383-90.
3. Beckerman NL. Living with lupus: a qualitative report. Soc Work Health Care 2011;50:330-43.
4. Fonseca R, Bernardes M, Terroso G, et al. Silent burdens in disease: fatigue and depression in SLE. Autoimmune Dis 2014;2014:1-9.
5. Pettersson S, Moller S, Svenungsson E, et al. Women's experience of SLE-related fatigue: a focus group interview study. Rheumatology 2010;49:1935-42.
6. Myint AM, Schwarz MJ, Muller N. The role of the kynurenine metabolism in major depression. J Neural Transm 2012;119:245-51.
7. Pettersson S, Bostrom C, Eriksson K, et al. Lifestyle habits and fatigue among people with systemic lupus erythematosus and matched population controls. Lupus 2015;24:955-65.
8. Tench CM, McCurdie I, White PD, et al. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology 2000;39:1249-54.
9. Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy States. Int J Tryptophan Res 2009;2:IJTR. S2097-19.
10. Yamashita M, Yamamoto T. Excessive brain tryptophan and kynurenic acid lead to abnormal social behavior in central fatigue induced by chronic sleep disorder. International Journal of Psychophysiology 2014;94:229-30.
11. Yamashita M, Yamamoto T. Tryptophan circuit in fatigue: from blood to brain and cognition. Brain Res 2017;1675:116-26.
12. Kolodziej LR, Paleolog EM, Williams RO. Kynurenine metabolism in health and disease. Amino Acids 2011;41:1173-83.
13. Henderson LM. Niacin. Annu Rev Nutr 1983;3:289-307.
14. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012;36:764-85.
15. Schmidt SK, Muller A, Heseler K, et al. Antimicrobial and immunoregulatory properties of human tryptophan 2,3-dioxygenase. Eur J Immunol 2009;39:2755-64.
16. Maes M, Leonard BE, Myint AM, et al. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:702-21.
17. Xiang ZY, Tang AG, Ren YP, et al. Simultaneous determination of serum tryptophan metabolites in patients with systemic lupus erythematosus by high performance liquid chromatography with fluorescence detection. Clin Chem Lab Med 2010;48:513-7.
18. Widner B, Sepp N, Kowald E, et al. Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology 2000;201:621-30.
19. Pertovaara M, Hasan T, Raitala A, et al. Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin Exp Immunol 2007;150:274-8.
20. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
21. Surowiec I, Johansson E, Torell F, et al. Multivariate strategy for the sample selection and integration of multi-batch data in metabolomics. Metabolomics 2017;13:114.
22. Idborg H, Oliynyk G, Rannar S, et al. SAT0181 Systems biology of SLE: Biochemical characterization of subgroups within SLE for improved diagnosis and treatment. Ann Rheum Dis 2013;7132(Suppl 3):532.3-532.
23. Bjelland I, Dahl AA, Haug TT, et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69-77.
24. Lisspers J, Nygren A, Soderman E. Hospital Anxiety and Depression Scale (HAD): some psychometric data for a Swedish sample. Acta Psychiatr Scand 1997;96:281-6.
25. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-3.
26. Mattsson M, Moller B, Lundberg I, et al. Reliability and validity of the fatigue severity scale in Swedish for patients with systemic lupus erythematosus. Scand J Rheumatol 2008;37:269-77.
27. Zonana-Nacach A, Roseman JM, McGwin G, et al. Systemic lupus erythematosus in three ethnic groups. VI: Factors associated with fatigue within 5 years of criteria diagnosis. LUMINA Study Group. LUpus in MInority populations: NAture vs Nurture. Lupus 2000;9:101-9.
28. Valko PO, Bassetti CL, Bloch KE, et al. Validation of the fatigue severity scale in a Swiss cohort. Sleep 2008;31:1601-7.
29. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the sledai. A disease activity index for lupus patients. Arthritis & Rheumatism 1992;35:630-40.
30. Lattanzi B, Consolaro A, Solari N, et al. Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). Arthritis Care Res 2011;63(S11):S112-S17.
31. Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther 2015;17:183.
32. Aeinehband S, Brenner P, Stahl S, et al. Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms. Brain Behav Immun 2016;51:47-55.
33. Eketjall S, Idborg H, Gustafsson JT, et al. TNF-a and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. Lupus Science & Medicine 2018;:-.
34. Elia G. Interferon-γ-inducible chemokines in systemic lupus erythematosus. Clin Ter 2015;166:e41-6.
35. Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther 2011;13:228.
36. Lee S, Kaneko H, Sekigawa I, et al. Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol 1998;37:1334-7.
37. Shah D, Wanchu A, Bhatnagar A. Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. Immunobiology 2011;216:1010-7.
38. Vogelgesang SA, Heyes MP, West SG, et al. Quinolinic acid in patients with systemic lupus erythematosus and neuropsychiatric manifestations. J Rheumatol 1996;23:850-5.
39. Stone TW, Stoy N, Darlington LG. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci 2013;34:136-43.
40. Rezzi S, Ramadan Z, Martin FP, et al. Human metabolic phenotypes link directly to specific dietary preferences in healthy individuals. J Proteome Res 2007;6:4469-77.
41. Badawy AA. Tryptophan availability for kynurenine pathway metabolism across the life span: Control mechanisms and focus on aging, exercise, diet and nutritional supplements. Neuropharmacology 2017;112:248-63.
42. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol 2003;81:247-65.
43. Brochez L, Chevolet I, Kruse V. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur J Cancer 2017;76:167-82.
44. Raison CL, Dantzer R, Kelley KW, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFNalpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010;15:393-403.
45. Kim S, Miller BJ, Stefanek ME, et al. Inflammation-induced activation of the indoleamine 2,3-dioxygenase pathway: Relevance to cancerrelated fatigue,. 2015:2129-36.
46. Pettersson S, Lundberg IE, Liang MH, et al. Determination of the minimal clinically important difference for seven measures of fatigue in Swedish patients with systemic lupus erythematosus. Scand J Rheumatol 2015;44:206-10.
47. Avina-Zubieta JA, Alarcon GS, Bischoff-Ferrari HA, et al. Measurement of fatigue in systemic lupus erythematosus: a systematic review. Arthritis Rheum 2007;57:1348-57.
48. Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016;75:1615-21.